Swine pneumonia is a great threat for pig industry around the world, which is usually accompanied with neutrophils infiltration in the airway. Although interleukin-8 (CXCL8) and its receptors, CXC chemokine receptor 1 and 2 (CXCR1/2) in human have been well documented, the expression and function of CXCR1/2 is still unknown in swine. To explore the feasibility to develop new veterinary anti-inflammatory drugs targeting porcine CXCR1/2, we detected CXCR1/2 expression in swine pneumonia through Real-Time PCR and immunohistochemistry for the first time. Two porcine CXCR1/2 antagonists, CXCL8 (3-72) N11R/G31P (pN11R) and CXCL8 (3-72) G31P (pG31P) were prepared and their anti-inflammatory effects were evaluated using cell chemotaxis assays and animal experiments. Our data showed that CXCR1/2 expression, which was closely related to neutrophil infiltration in the lung, was significantly up-regulated in swine pneumonia. The pN11R and pG31P could effectively inhibit the directional migration of neutrophils in vitro. In vivo data also indicated that both pN11R and pG31P significantly relieved LPS-induced pneumonia in mice through decreasing the expression of TNF-α, CXCL8, and IL-1β, and inhibiting neutrophil influx into the lung. pG31P was more efficient. Our study suggested that it is possible to develop new veterinary anti-inflammatory drugs targeting porcine CXCR1/2, and pG31P is a promising candidate.
The pig industry around the word has been suffering from respiratory diseases, especially pneumonia, which caused increasing mortality and decreasing production performance 1 . Swine pneumonia usually caused by co-infection with multiple pathogens, which bring a lot of obstacles to pneumonia treatment 2, 3 . Treatment of swine pneumonia nowadays mainly relies on antibiotics or vaccine. However, many countries restrict the use of antibiotics since the drug residues in food have become a serious issue 4 . Therefore, it is urgent to develop a broad-spectrum, less residual anti-inflammatory drug for pneumonia treatment.
Swine pneumonia is always accompanied with migration of neutrophils in the interstitium and broncheoalveolar space. Therefore, neutrophils are considered to play a key role in pneumonia development and rational control of neutrophils exudation and migration represent a potential therapy for swine pneumonia 5 . Previous studies indicated that neutrophils infiltration primary mediated by interleukin-8 (CXCL8) and its specific receptors, CXCR1 and CXCR2 6, 7 . CXCL8 is a member of CXC chemokines, which was first discovered as a neutrophil chemotactic factor 8 . It can be can be produced by varieties of cells, such as neutrophils, monocytes, bronchial endothelial cells and airway smooth muscles cells [9] [10] [11] [12] . CXCR1/2 belong to G-protein coupled receptor family, which are expressed on leukocytes, including neutrophil, monocytes, CD8 + T cells, etc. 13, 14 . CXCL8 exerts its effects on neutrophils by binding with CXCR1/2. Currently, CXCL8 and CXCR1/2 have been proved to plays a central role in promoting neutrophils activation and recruitment to inflammatory site 15 . Therefore, successful blocking the interaction of CXCL8 and CXCR1/2 is a great therapy for inflammation control 16 .
During the past few decades, many antagonists target CXCL8-CXCR1/2, including Reparixin, SCH527123, SB22502 and CXCL8 K11R /G31P (hG31P) were developed [17] [18] [19] [20] [21] . Reparixin, (R) (-)-2-(4-isobutylphenyl) propionyl methansulfonamide), is a CXCR1/2 allosteric antagonist which mainly acts on the transmembrane domain of CXCR1/2 and induces the rearrangements of 3rd and 6th α-helix, thereby preventing downstream signal transduction and inhibiting neutrophil recruitment. SCH527123, 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide, is an another allosteric antagonist of CXCR1/2, which could potently bind to CXCR1/2 and are difficult to dissociate, thereby inhibiting the interaction between CXCL1 or CXCL8 with CXCR1/2, affecting downstream signal transduction and controlling neutrophil infiltration 22, 23 . Several studies have shown that Reparixin and SCH527123 could relieve acute lung injury, COPD and asthma etc 19, 24, 25 . SB22502, (N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea), the first non-peptide selective inhibitor of CXCR2, was reported to inhibit CXCL8 and GRO-α-mediated Ca 2+ mobilization, thereby reducing neutrophil chemotaxis both in vitro and in vivo. hG31P, a CXCL8 mutant which shows higher affinity to CXCR1/2 than CXCL8, could inhibit about 50% neutrophils recruitment in airway 26, 27 . It was reported that hG31P has a good efficacy in the treatment of multiple inflammatory diseases, such as acute lung injury, COPD, et al. 18, 27, 28 .
It was demonstrated that CXCL8 is vital for inducing neutrophils migration to resist exogenous infection in swine [29] [30] [31] . However, the function of swine CXCR1/2 are largely unexplored. In this study, we aimed to explore the relationship between CXCR1/2 and swine pneumonia, and developed a promising anti-inflammatory drug candidate targeting porcine CXCR1/2. Our study hopes to provides a new idea for swine anti-inflammatory drugs development.
Results

CXCR1/2 expression in lung tissue of swine with pneumonia.
In this study, 127 cases of swine pneumonia were collected, including bronchopneumonia (17 cases), interstitial pneumonia (81 cases), serous pneumonia (8 cases) and suppurative pneumonia (21 cases). The alveolar septa in interstitial pneumonia were notably thickened by interstitial infiltration of numerous lymphocytes and few neutrophils. On the other hand, neutrophils infiltration in different levels in bronchioles and alveoli were observed in suppurative pneumonia, bronchopneumonia, and serous pneumonia. The expression of CXCR1 and CXCR2 was first examined by Real-Time PCR. Both CXCR1 and CXCR2 expression were up-regulated in all pneumonia samples. In addition, the expression of CXCR1 was significantly higher than CXCR2. Bronchopneumonia and suppurative pneumonia presented higher CXCR1/2 expression than interstitial pneumonia and serous pneumonia (Fig. 1b ). The expression of CXCR1/2 was further examined by immunohistochemical staining of pneumonia samples. It was found that no expression of CXCR1/2 was observed in the normal lung tissues. However, the CXCR1/2 proteins were detected in neutrophils, which infiltrated in the lung in pneumonia ( Fig. 1a ). Additionally, the protein expression of CXCR1/2 were consistent with their mRNA expression pattern, which indicated that CXCR1/2 expression was significantly increased in swine pneumonia (Fig. 1c ).
The impact of pN11R and pG31P on neutrophil migration in vitro.
In this study, we also expressed antagonist pN11R and pG31P targeting porcine CXCR1/2 ( Fig. 2 ) and evaluated their chemotactic effects on neutrophil in vitro at first. As showed in Fig. 3a , pCXCL8, pN11R, and pG31P could induce neutrophil migration. However, the ability of pN11R and pG31P inducing neutrophil migration was decreased by about 50% compare with pCXCL8 ( Fig. 3b ).
The impact of pN11R and pG31P on LPS-induced mouse pneumonia. We next assessed the impact of pN11R and pG31P on inflammatory response by using a mouse pneumonia model. After 24 h of induction, the saline-challenged mice showed normal histological appearance. However, all LPS-challenged mice suffered from pneumonia. Hemorrhage and an increased number of neutrophils infiltration in the lung were observed in LPS-challenged and saline-treated mice. Treatment with pCXCL8 enhanced hemorrhage and neutrophils infiltration in the lung, whereas treatment with pN11R and pG31P significantly reduced hemorrhage and neutrophils infiltration in the lung (Fig. 4 ). In addition, cells in BALF were collected and counted to determine the migration of both number and type of cells into alveoli. Almost all cells migrated into BAL were neutrophils. The neutrophils were almost invisible in BALF of saline-challenged mice, while 5.2 × 10 6 cells for LPS-challenged mice, 8.6 × 10 6 cells for LPS + pCXCL8-challenged mice, 4.1 × 10 6 cells for LPS + pN11R-challenged mice 3.4 × 10 6 cells for LPS + pG31P-challenged mice. It revealed that LPS challenge significantly increased the number of neutrophils in BAL. Treatment of LPS-challenged mice with pCXCL8 significantly increased the number of neutrophils. Conversely, treatment with pN11R/pG31P significantly reduced the number of neutrophils in BAL, although the number of neutrophils was still higher than control group (Fig. 5a) . Additionally, the level of neutrophil degranulation marker, MPO, in the lung of pN11R/pG31P-treated mice was also dramatically lower than that in the saline-treated group (Fig. 5b ). Since the inflammatory response is strongly related to the expression of inflammatory factors, we examined the impact of our antagonist on the expression of inflammatory factors, including TNF-α, IL-1β and CXCL8. As it was shown, treatment with pN11R or pG31P reduced the expression of TNF-α, IL-1β and CXCL8. Among them, the expression of CXCL8 in the pN11R/pG31P-treated group was even lower than that in the control group ( Fig. 6 ).
Discussion
Pneumonia, the main disease for swine death, has caused huge losses to swine industry for a long time. Excessive neutrophil infiltration is usually found to be the primary pathological feature of pneumonia, which always leads to lung damage 32, 33 . CXCL8 has been considered as an essential chemokine for neutrophil activation and recruitment. Blocking the binding of CXCL8 to its receptors, CXCR1/2, can effectively limit neutrophils recruitment and slow down inflammatory response 34, 35 . In this study, the relationship between CXCR1/2 and swine pneumonia were determined using Real-Time PCR and immunohistochemical staining. The results revealed that the expression of CXCR1/2 in swine pneumonia were up-regulated. Interestingly, the expression of CXCR1/2 in bronchopneumonia and suppurative pneumonia were significantly higher than that in interstitial pneumonia and serous pneumonia (Fig. 1b,c) . Immunohistochemical results showed that CXCR1/2 were expressed in neutrophil in pneumonia ( Fig. 1a) . Interstitial pneumonia is a type of proliferative pneumonia that is usually caused by viral infection. It is characterized by the proliferation of type II pneumocyte and less neutrophils infiltration. Bronchopneumonia, suppurative pneumonia and serous pneumonia belong to exudative pneumonia, which are mainly generated by bacterial infections or mixed infections and characterized by increasing neutrophils Figure 1 . The expression of CXCR1/2 in swine pneumonia. Immunohistochemical staining showed that CXCR1/2 appeared undetectable expression in normal lung, while were positively expressed in neutrophils, which infiltrated in the lung in swine pneumonia (arrow) (a). Both mRNA (b) and protein (c) expression of CXCR1/2 were up-regulated in all above pneumonia, and the expression of CXCR1 was significantly higher than CXCR2 (P < 0.05). And the CXCR1/2 expression in bronchopneumonia and suppurative pneumonia are higher CXCR1/2 than that in interstitial pneumonia and serous pneumonia (P < 0.01). *P < 0.05, **P < 0.01, ***P < 0.001, unpaired t-test, two-tailed. infiltration 32 . Histopathologically, the degree of neutrophil infiltration in suppurative pneumonia and bronchopneumonia were more obvious than that in serous pneumonia and interstitial pneumonia. Therefore, we concluded that the expression of CXCR1/2 in pneumonia was positively correlated with the number of neutrophil infiltrated in the lung. Our results demonstrated that CXCR1/2 expression was closely associated with swine pneumonia. Numerous studies showed that the expression of CXCR1 and/or CXCR2 increased in many inflammatory disease, such as ulcerative colitis and hyperoxia-induced lung injury, so that massive neutrophils could be recruited into the site of inflammation 36, 37 . Reduction of CXCR1/2 expression or inhibition of CXCR1/2 binding would be an effective approach to inhibit neutrophil recruitment and relieve inflammation [38] [39] [40] . All these studies indicated that CXCR1/2 could be potential target for swine pneumonia therapeutic. Previously, a small molecular CXCL8 antagonist, hG31P was developed by Lee et al. 41 . They mutated Arg residue at site 11 of the main binding site of human CXCL8 to Lys11 and Pro residue at site 31 of the first β-turn of human CXCL8 to Gly to generate hG31P. It has a higher affinity to CXCR1/2 and was able to inhibit downstream signal transduction and, therefore, limit neutrophil migration 42, 43 . Furthermore, it was also reported that hG31P can effectively inhibit neutrophil recruitment and reduce pathology of lung in mice models 40, 44 . Porcine CXCL8 shares 73.6% homology on amino acid with hCXCL8, and has the same ELR + sequence and cysteine site with hCXCL8. In this study, we substituted Arg and Pro for Lys11 and Gly31 to prepare pN11R, substituted Pro for Gly31 to prepare pG31P ( Fig. 2a ). Previous evidences showed that inhibiting the migration of neutrophils into the lung is critical in limiting lung inflammation 45 . Thereby, we firstly determined the impact of pN11R and pG31P on neutrophil migration in vitro. It was found that pN11R and pG31P could dramatically inhibit neutrophil migration in vitro individually. In addition, the in vivo effect on neutrophil migration response to LPS was also evaluated with the LPS-challenged mouse model. Histopathological results showed lower neutrophil infiltration in the lung of N11R/G31P and PCXCL8 G31P protein expression. The gene of porcine CXCL8 N11R/G31P and CXCL8 G31P were cloned into PGEX 6P-1, and then transformed into E. coli Rosetta (DE3) (a-c). Recombinant proteins CXCL8 N11R/G31P (pN11R) and CXCL8 G31P (pG31P) were induced by IPTG, treated with Prescission Protease, and then purified through GSTrap TM FF. Two proteins molecular weight of 10KD were finally obtained (d). The recombinant proteins could be identified by anti-human CXCL8 antibody (e).
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(2020) 10:1210 | https://doi.org/10.1038/s41598-020-57737-w www.nature.com/scientificreports www.nature.com/scientificreports/ pN11R/pG31P-treated mice. MPO activity and neutrophils number in the BALF of LPS-challenged mice were significantly elevated compared to the control group. Treatment with pCXCL8 enhanced MPO activity and neutrophils migration in the lungs of LPS-challenged mice. By contrast, treatment with pN11R and pG31P reduced MPO activity and neutrophil migration. These results suggested that pN11R and pG31P could down-regulate neutrophil migration, therefore, contribute to limiting lung inflammation.
In addition, LPS stimulated the expression of TNF-α, IL-1β and CXCL8, however, treatment with pN11R/ pG31P significantly decreased each of them. Cytokines, including IL-1β, TNF-α and CXCL8 were good indicators of lung inflammation 46 . In cases of pneumonia, inflammatory factors released in the lung could lead to increasing vascular permeability, thus resulting in rapid recruitment of neutrophils 6 . Neutrophils could express IL-1, TNF-α and CXCL8 47 . Local secretion of these cytokines could induce more neutrophil recruitment and inflammatory mediator release 15, 48 . Indeed, the levels at which neutrophils secreted these cytokines are closely related to their numbers. Decreasing expression of TNF-α, IL-1β and CXCL8 suggested slight neutrophils infiltration and inflammatory response. These demonstrated that pN11R and pG31P could reduce the expression of inflammatory mediator, thereby, inhibiting inflammatory response.
Furthermore, we also compared the different impact on neutrophil migration between pN11R and pG31P, and found that although there was no difference in inducing neutrophil migration in vitro, the pG31P-treated mice showed lower MPO activity, neutrophils exudation in BALF and TNF-α expression ( Figs. 5a and 6) , it suggested that pG31P may be a candidate for the further research of swine antagonist. Fang Li et al. developed hG31P based www.nature.com/scientificreports www.nature.com/scientificreports/ on CXCL8 K11R, a high agonist of neutrophil CXCR1/2 49 . However, our research demonstrated that it was possible to reduce the activity of porcine CXCL8 on inducing neutrophil migration by only mutating Pro into Gly31, and substituting Arg for Asn11 in pN11R might not increase the anti-inflammatory effect.
In summary, our study indicated that it is possible to develop veterinary anti-inflammatory drug by targeting CXCR1/2. The pG31P, which can significantly reduce neutrophils infiltration and relieve lung inflammation, is a promising drug candidate to treat swine pneumonia.
Materials and Methods
Ethics statement. All animals were treated in strict accordance with the Guidelines for Laboratory Animal Use and Care, which was approved by the Laboratory Animal Monitoring Committee of Huazhong Agricultural University.
Sample collection. Totally, 127 cases of swine pneumonia were collected in Hubei province, China from
March 2017 to December 2018. The samples of lung were fixed with 10% formalin for histopathological analysis. For molecular biological analysis, samples were stored at -80 °C. The types of pneumonia were confirmed by gross and histopathological observation. CXCR1/2 mRNA expression. Total RNA was extracted from lung samples using TRIzol TM Reagent (Invitrogen, Carlsbad, CA, U.S.A.). The cDNA of CXCR1/2 were synthesized from 1 μg total RNA using Prime Script TM RT Kit with gDNA Eraser (Takara, Japan). Then Real-Time PCR was performed using SYBR-Green Real-Time PCR Master Mix (TaKaRa, Japan) according to the manufacturer's instructions. Primers used in Real-Time PCR reactions were listed in Table 1 . Cycling parameters were 95 °C for 10 min; 40 cycles at 94 °C for 30 sec; 56 °C for 30 sec; 72 °C for 1 min.
Immunohistochemistry. Since porcine CXCR1/2 specific antibodies were not commercially available, CXCR1 and CXCR2 were used individually for mouse immunization to prepare polyclonal antibodies. Ten 6-week-old female BALB/c mice were respectively immunized with 100 μg of recombinant porcine CXCR1 (1-90 amino acid) and CXCR2 (1-88 amino acid) in Freund's adjuvant (Sigma, ST Louis, MO, U.S.A.) four times at biweekly intervals. One week after the final immunization, mice were bled and sera were obtained and fractionated into IgG by a protein A agarose column (GE, Piscataway, NJ, U.S.A.) 50 . The purified sera were further detected by indirect enzyme-linked immunosorbent assay (ELISA) and western blot, and finally used to immumohistochemical staining. For immunohistochemistry, the slides were deparaffinized, rehydrated, and treated with 3% H 2 O 2 . After rinsing in PBS, the slides were blocked with normal goat serum followed by incubating with anti-CXCR1 and CXCR2 antibodies (1:100) at 4 °C overnight. After rinsing with PBS, the slides were incubated with HRP-conjugated goat anti-mouse IgG (Dako, Glostrup, Denmark) at room temperature for 40 min and then were visualized with DAB Detection Kit (GK500710, Gene Tech, Shanghai, China). Six views in different fields were randomly collected from slice under microscope (Nikon, Japan). The positive rate of each slice was analyzed by Leica Image Scope software (Wetzlar, Germany).
Preparation of porcine CXCR1/2 antagonist. The gene of porcine CXCL8 N11R/G31P and CXCL8 G31P (Fig. 2a ) were synthesized at Sangon Biotech (Shanghai) Co., Ltd. and amplified by PCR (5′-TAGGATCCGCAGAACTTCGATGCCAGTG-3′ and 5′-CGCTCGAGTTATTGCTTCTCAGTTCTCT TCAAAAA-3′). Cycling parameters were 95 °C for 10 min; 32 cycles at 94 °C for 30 sec; 56 °C for 30 sec; 72 °C for 
Neutrophil chemotaxis assay.
The under-agarose chemotactic model was performed as described previously 51 . Briefly, 3 mL 1.2% agarose solution included 50% 1 × HBSS with Ca 2+ and Mg 2+ , 50% RPMI 1640 culture medium, and 20% heat-inactivated FBS was put in the 6-well culture plate. Once the agarose solidified, 3 wells in a straight line, 3.5 mm in diameter and 2.8 mm apart, were generated on the gel. Neutrophils were isolated from peripheral blood of healthy pigs using Porcine Neutrophil Isolation Kit (Solarbio, Beijing, China) and added into the two side wells (10 μL/10 7 cells/well). The porcine CXCL8 (pCXCL8), pN11R, pG31P, and cell culture medium were added into the middle well (10 μL/1 μg/well) respectively. The gels were incubated at 37 °C/5% CO 2 for 6 h, and the migration distance of neutrophil was measured under microscope (Leica, Wetzlar, Germany).
Animal procedures. [18] [19] [20] g female BALB/c mice (7-week-old), which purchased from Laboratory Animal Center of Huazhong Agricultural University (Wuhan, China), were randomly divided into 5 groups, each group of 9 mice. The mice were anesthetized by diethyl ether and held on a plate titled 45°. Mice in the control group were intranasal inoculated with 20 μL normal saline. Mice in the groups 1-4 were first intranasally inoculated with 10 μL (10 μg/μL) lipopolysaccharide (LPS) to induce pneumonia. Then, groups 1-4 were intranasal inoculated with 10 μL (500 μg/kg) pCXCL8, 10 μL (500 μg/kg) pN11R, 10 μL (500 μg/kg) pG31P, and 10 μL normal saline respectively. After 24 h of inoculation, all mice were anesthetized with sodium pentobarbital (100 μl, 75 mg/ ml). 3 mice in each group were collected lung for histopathological examination, 3 mice in each group were collected lung for molecular biological detection, and 3 mice in each group were collected bronchiolar alveolar lavage (BAL) for neutrophil count.
Lung histopathology. Mice lung tissues was fixed in 10% formalin, embedded in paraffin, sectioned into 4 μm thickness, and stained with hematoxylin-eosin (H.E.). The histopathological changes were observed and recorded under a microscope (NiKon, Tokyo, Japan).
Bronchiolar alveolar lavage collection. The lung of mice was lavaged three times with 1 mL normal saline. Lavage fluid was mixed with red blood cell lysis buffer and centrifuged for 10 min at 1,750 g. The pellet cells were resuspended in the 1 mL normal saline. 10 μL cell suspension was adhered to glass slides and stained using H.E. Meanwhile, 10 μL cell suspension was added to the cell-count boards to count the number of neutrophils.
Myeloperoxidase (MPO) assay. About 100 mg frozen lung was homogenized with 1 mL saline, and centrifuged at 12,000 rpm for 10 minutes at 4 °C. The supernatant was used for MPO activity analysis according to the instruction of Mouse Myeloperoxidase ELISA Kit (Solarbio, Beijing, China). 
